Clinical Trial Detail

NCT ID NCT03878719
Title Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Array BioPharma
Indications

melanoma

Therapies

Binimetinib + Encorafenib

Age Groups: child

Additional content available in CKB BOOST